Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 3 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Pricing and Reimbursement in Europe - Introduction | 7 | 1 |
| GBI Research Report Guidance | 7 | 1 |
| Pricing and Reimbursement in Europe - Overview | 8 | 16 |
| Healthcare Expenditure Highly Correlated with GDP | 10 | 2 |
| Relation between Pharmaceutical Expenditure and GDP | 12 | 1 |
| Overview of Pharmaceutical Regulations in Europe | 13 | 1 |
| Negotiations | 14 | 1 |
| International Price Referencing | 14 | 1 |
| Internal Reference Pricing | 15 | 1 |
| Tendering | 15 | 1 |
| Price Capping of Generic Pharmaceuticals | 15 | 1 |
| Use of Positive and Negative Formulary | 16 | 1 |
| Value Based Pricing and Risk-Sharing Models | 16 | 2 |
| Increased Focus on Evidence-based Medicine and Health Technology Assessment (HTA) | 18 | 1 |
| Role of Pharmacoeconomics in Pricing and Reimbursement | 19 | 1 |
| EU Single Pricing Still an Unresolved Issue | 20 | 1 |
| Recent Major Changes in Pricing and Reimbursement of Drugs in Europe | 21 | 1 |
| The UK to Adopt VBP Replacing PPRS from 2014 despite Concerns of Companies and Experts Alike | 21 | 1 |
| Major Challenge Regarding VBP Adoption in the UK | 21 | 1 |
| France Decreases Reimbursement for Drugs with Moderate Clinical Benefits Along With Overall Price Cuts | 21 | 1 |
| Benefit Assessment Led Price Negotiation, Price Freeze and Mandatory Discounts Key Features Of German P&R Changes | 22 | 1 |
| Italian P&R Scene Dominated By Price Cuts and Changes in Reference Price Level | 22 | 1 |
| Main Austerity Measures in Spain Include 7.5% Rebate for In-Patent Drugs and Price Cuts for Generics | 22 | 1 |
| Renewed P&R Cut Of 7% in Czech Republic and Proposed Changes in VAT for 2012 And 2013 | 22 | 1 |
| Expenditure on Reimbursement of Medicines Fixed At 17% of the NHF in Poland | 23 | 1 |
| Levy on Sale of Reimbursed Drugs in Hungary to Go Up To 20%; Payment-By-Result another Major Move | 23 | 1 |
| Pricing and Reimbursement in Europe - The Top Five Countries of Europe | 24 | 27 |
| The UK | 25 | 1 |
| Healthcare System in the UK | 25 | 1 |
| Healthcare expenditure Other Developed Countries More Prominent Healthcare Spenders | 26 | 1 |
| Pricing and Reimbursement Process in the UK | 27 | 2 |
| Key Trends | 29 | 1 |
| Changeover to the New PPRS in 2009 Key Points | 29 | 1 |
| Value-Based Pricing In The Future | 30 | 1 |
| Major Challenges | 30 | 1 |
| France | 31 | 1 |
| Healthcare System in France | 31 | 2 |
| Pricing and Reimbursement Process in France | 33 | 1 |
| Important Players | 33 | 1 |
| Financing Law of Social Security (LFSS) 2011 | 34 | 2 |
| Key Trends | 36 | 1 |
| Pharmaceutical Price Cuts Including Parallel Import Drugs | 36 | 1 |
| CEPS Adjustments to Drug Pricing Methods | 36 | 1 |
| Generics Substitution Missed Targets in 2010 | 37 | 1 |
| CEPS Imposes Reference Prices for Branded Antihypertensive From 2011 | 37 | 1 |
| Reimbursement Restrictions for Drugs of Limited Clinical Merit Rating | 38 | 1 |
| Exclusion of Benign Hypertension from Reimbursement | 38 | 1 |
| Reimbursement Cuts for Drugs with Moderate Clinical Benefit and Medical Devices | 38 | 1 |
| Swift End to Reimbursement of Drugs That Offer Minimal Clinical Benefit | 39 | 1 |
| Major Challenges | 39 | 1 |
| Germany | 40 | 1 |
| Healthcare System in Germany | 40 | 1 |
| Pricing and Reimbursement Process in Germany | 41 | 1 |
| Key Trends | 42 | 1 |
| Cost-Containing Measures According To the AMNOG For Patented Drugs | 43 | 1 |
| Impact of Pricing Reform Pharmaceutical Manufacturers No Longer Able To Fix Prices | 44 | 1 |
| Expansion of the Reference-Pricing System | 44 | 1 |
| 16% Rebate on Non-Reference Drug Sales Further Cost Containment | 44 | 1 |
| Rebate Contracts between Health Insurance Funds and Manufacturers of Generics | 44 | 1 |
| Reimbursement Prices | 44 | 1 |
| Major Challenges | 45 | 1 |
| Italy | 45 | 1 |
| Healthcare System in Italy | 45 | 1 |
| Pricing and Reimbursement Process in Italy | 45 | 1 |
| Key Trends | 46 | 1 |
| Off-Patent Drugs and Generics Prices Targeted By Lowering Their Reference Prices | 46 | 1 |
| Margin Cuts Of Wholesaler and Pharmacists On Top Of Price Limits | 46 | 1 |
| New List of Innovative Drugs that Regions Obligated to Reimburse Provide Incentive for Pharmaceutical Companies | 46 | 2 |
| Major Challenges | 48 | 1 |
| Impact on Profitability of Branded Drugs by Innovator Companies due to Prescription of Cheapest Version of a Drug | 48 | 1 |
| Challenge for Generics Producers | 48 | 1 |
| Spain | 48 | 1 |
| Healthcare System in Spain | 48 | 1 |
| Pricing and Reimbursement Process in Spain | 48 | 1 |
| Key Trends | 49 | 1 |
| Change in the Reference Pricing System | 49 | 1 |
| Drugs Marketed For Over 10 Years to Have Increased Price Reduction | 49 | 1 |
| Rebates Imposed On Patented and Orphan Medicines | 49 | 1 |
| Average Price Cut of 25% on Generic Drugs | 49 | 1 |
| Further Pricing Pressure Due To Tendering System and Other Demand-Side Initiatives by Regional Authorities | 50 | 1 |
| Major Challenges | 50 | 1 |
| Pricing and Reimbursement in Europe - Eastern Europe | 51 | 10 |
| Czech Republic | 52 | 1 |
| Healthcare System in Czech Republic | 52 | 1 |
| Pricing and Reimbursement Process in the Czech Republic | 52 | 1 |
| Key Trends | 53 | 1 |
| Reduction By 7% of Drug Prices for Drugs Not Reviewed By SUKL Valid For One More Year | 53 | 1 |
| Changes in VAT on Medicines Expected From 2012 | 53 | 1 |
| Major Challenges | 53 | 1 |
| Poland | 53 | 1 |
| Healthcare System in Poland | 53 | 1 |
| Pricing and Reimbursement Process in Poland | 54 | 1 |
| Key Trends | 54 | 1 |
| Removal of the Proposed 3% Reimbursement in the Initial Draft of Reimbursement Act | 54 | 1 |
| Expenditure on Reimbursement of Medicines Fixed At 17% of the Total Annual Budget of Polish NHF Could Spell Well For Innovators | 55 | 1 |
| Fixed Price on Reimbursed Medicines to Hurt Profitability | 55 | 1 |
| Margins of Wholesalers to Be Reduced Gradually | 55 | 1 |
| Risk-sharing Agreements for Costly Innovative Drugs | 55 | 1 |
| Extension of Reference Pricing For High-Cost Drugs in Hospitals May Affect Prices | 56 | 1 |
| Major Challenges | 56 | 1 |
| Romania | 56 | 1 |
| Pricing and Reimbursement Process in Romania | 56 | 1 |
| Key Trends | 57 | 1 |
| New International Reference Pricing Will Give a Boost to Generics Producers | 57 | 1 |
| Change in Reference Price Calculation to Affect High-Cost Drugs Revenue and Increase Co-Payment for Patients | 57 | 1 |
| Major Challenges | 58 | 1 |
| Hungary | 58 | 1 |
| Healthcare System in Hungary | 58 | 1 |
| Pricing and Reimbursement Process in Hungary | 58 | 1 |
| Key Trends | 59 | 1 |
| Price Fixing Of Composite Drugs to Deliver Savings | 59 | 1 |
| Increase in Levy on Revenues from Reimbursed Drugs Sale from 12% to 20% | 59 | 1 |
| Payment-by-Results to Be Introduced As Part of the Structural Reform Measures | 60 | 1 |
| Generics Set for Further 5% Reference Price Reductions | 60 | 1 |
| Major Challenges | 60 | 1 |
| Pricing and Reimbursement in Europe - Scandinavia | 61 | 3 |
| Norway | 62 | 1 |
| Finland | 62 | 1 |
| Denmark | 62 | 2 |
| Pricing and Reimbursement in Europe - Appendix | 64 | 5 |
| Market Definitions | 64 | 1 |
| Abbreviations | 64 | 2 |
| Research Methodology | 66 | 2 |
| Healthcare System | 66 | 1 |
| Pricing and Reimbursement Process | 67 | 1 |
| Key Trends | 67 | 1 |
| Major Challenges | 67 | 1 |
| Contact Us | 67 | 1 |
| Disclaimer | 67 | 1 |
| Sources | 68 | 1 |